Teva Pharmaceutical Industries Limited Ordinary Shares

About Teva Pharmaceutical Industries Limited Ordinary Shares

Teva Pharmaceutical Industries sells pharmaceutical products through generic and innovative-drug businesses. It makes money from medicine sales; the supplied evidence specifically identifies generic Revlimid and innovative drugs as contributors to recent revenue, but does not provide segment shares or customer-level detail. Teva generated $17.3 billion of revenue and $1.4 billion of net income in fiscal 2025, compared with $16.5 billion of revenue and a $1.6 billion net loss in 2024. Its second-quarter 2026 revenue was approximately $4.1 billion, down 1% year over year in U.S. dollars.

Notable Price Movement

1. Aug 3-7$35.361.00%

   Teva rose $2.76, or 8.71%, from $31.67 on July 28 to $34.43 on August 4. The decisive move came July 29, when the stock jumped to $34.71 on 17.8 million shares after second-quarter results showed sales above expectations and a higher 2026 revenue outlook, despite an earnings miss. Shares extended gains to $35.41 on July 30, then gave back $0.40 by July 31 and slipped another $0.55 over August 3-4. The reported catalysts were innovative-drug growth and the raised revenue view, while Emalex acquisition costs weighed on profit and lower generic Revlimid sales constrained revenue. The supplied evidence identifies no additional market-wide driver.

   3 sources

Stories & Analysis

TEVA Looks 80.2% Overvalued on GF Value™GuruFocus · 23h agoTEVA Looks 80.2% Overvalued on GF Value™ as Insider Selling PersGuruFocus · 23h agoInvestment fund tied to Teva (NYSE: TEVA) director plans share saleStock Titan · 23h agoTeva Data Show Healthcare Providers Prioritize Tolerability and Long-Term Response in Tardive Dyskinesia Treatment SelectionQuiver Quantitative · 1d agoTeva Reports Real-World UZEDY Data Showing Better Treatment Continuity, Lower Healthcare Use and Cost Savings in Schizophrenia and Bipolar I DisorderQuiver Quantitative · 1d agoTeva Announces Positive Long-Term SOLARIS Data for Investigational Once-Monthly Olanzapine LAI TEV-'749 in SchizophreniaQuiver Quantitative · 1d agoUp to 96% of people with TD still felt its impact after two years without a TD medicineStock Titan · 1d agoTeva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare CostsYahoo Finance · 1d ago